A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases.

MLA

Redeker, Imke, et al. “A Bayesian Model to Analyse the Association of Comorbidities with Biosimilar Treatment Retention in a Non-Medical Switch Scenario in Patients with Inflammatory Rheumatic Musculoskeletal Diseases.” Arthritis Research & Therapy, vol. 26, no. 1, Sept. 2024, p. 155. EBSCOhost, https://doi.org/10.1186/s13075-024-03386-7.

APA

Redeker, I., Moustakis, S., Tsiami, S., Baraliakos, X., Kiefer, D., Andreica, I., Buehring, B., Braun, J., & Kiltz, U. (2024). A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases. Arthritis Research & Therapy, 26(1), 155. https://doi.org/10.1186/s13075-024-03386-7

Chicago

Redeker, Imke, Stefan Moustakis, Styliani Tsiami, Xenofon Baraliakos, David Kiefer, Ioana Andreica, Björn Buehring, Jürgen Braun, and Uta Kiltz. 2024. “A Bayesian Model to Analyse the Association of Comorbidities with Biosimilar Treatment Retention in a Non-Medical Switch Scenario in Patients with Inflammatory Rheumatic Musculoskeletal Diseases.” Arthritis Research & Therapy 26 (1): 155. doi:10.1186/s13075-024-03386-7.